CDKN2A and metastatic neoplasm: Furthermore, CDKN2A deletion, PTEN deletion, and MYC amplification occurred more frequently in metastatic (7.4%, 3.3%, and 6.7%, respectively) than non-metastatic disease (4.2%, 1.6%, and 3.8%, respectively).